Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BMS Appoints SVP, BD Head | Contract Pharma
Promotions & Moves

BMS Appoints SVP, BD Head

Biondi to lead the development of strategic partnerships and pursue scientific innovations


 
Paul Biondi has been appointed senior vice president, head of business development at Bristol-Myers Squibb. He reports to Charlie Bancroft, chief financial officer. Mr. Biondi will lead the development of strategic partnerships and pursue scientific innovations across commercial, development, discovery and technology platforms to complement the company’s internal R&D pipeline. Most recently, he served as senior vice president, head of R&D Operations at BMS.

“Paul has established himself as a dynamic and collaborative leader at Bristol-Myers Squibb and made significant contributions over the past 10 years to our success in R&D and business development,” said Mr. Bancroft. “With deep knowledge of our R&D strategy and portfolio, strong business expertise and understanding of the healthcare landscape, Paul is the ideal leader to continue our pursuit of external innovation that helps Bristol-Myers Squibb develop and deliver transformational medicines for patients with serious diseases.”

As head of R&D Operations, Mr. Biondi led an organization focused on optimizing delivery of the company’s pipeline, managing the R&D portfolio and project management as well as early- and late-stage clinical operations providing strategic insights and operational excellence across R&D.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters